吉非替尼对EGFR基因突变型晚期肺癌患者的影响

Effects of gefitinib on EGFR mutation in the prognosis of advanced lung cancer

目的探讨聚合酶链反应—单链构象多态性(PCR-SSCP)技术检测晚期肺癌患者表皮生长因子受体(EGFR)基因突变的敏感性,观察靶向性药物吉非替尼对EGFR基因突变型肺癌患者的临床疗效。方法从54例晚期肺癌患者的肿瘤组织中提取DNA,用PCR-SSCP技术检测其EGFR基因突变情况;并对EGFR基因突变患者进行吉非替尼靶向治疗。结果肺癌组织中检出EGFR基因突变28例,突变率为51.9%;EGFR基因突变多见于女性和肺腺癌患者。28例EGFR基因突变型患者行吉非替尼治疗后的客观有效率为53.6%,病情控制率为92.9%;其生存率1 a以上57.1%,2 a以上28.6%,3 a以上14.3%。结论PCR-SSCP检测肺癌EGFR基因突变具有高度敏感性,以其EGFR基因突变结果为依据对晚期肺癌患者选用靶向治疗,有明显疗效。

Objective To analyze the sensitivity of the PCR-SSCP which was used to detect lung cancer epidermal growth factor receptor （EGFR） gene mutations, screen the EGFR mutations lung cancer patients and assess the clinical efficacy of gefitinib. Methods DNA was extracted from tumor tissue of 54 lung cancer patients. EGFR mutations were measured by PCR-SSCP. The patients with EGFR genetic mutation were treated by gefitinib. Results 28 cases of lung cancer EGFR mutations were detected from 54 cases of lung cancer, the mutation rate was 51.9% ; EGFR mutations were more common in female patients and patients with lung adenocarcinoma. Objective response rate in 28 cases of lung cancer EGFR mutations after treatment of gefitinib was 53.6%, and the disease control rate was 92.9% ; More than 1-year survival rate was 57.1%, more than 2-year survival rate was 28.6%, more than 3-year survival rate was 14.3%. Conclusions PCR-SSCP detection of lung cancer EGFR mutations has a high degree of sensitivity, On the bases of the results of EGFR mutations, selective therapy targeted patients with advanced lung cancer has obvious advantages.